RIPK2 and central nervous system cancer: To explore the biological role of RIP2 in glioma cells, we first evaluated the viability of six types of glioma cells (T98G, T98G/TR, U87MG, U87MG/TR, U251, and SW1783) upon treatment with TMZ at different concentrations.